BILHI Genetics

bilhigenetics.com

Bilhi Genetics is a biotech company at the edge of biotechnology and digital technologies. We ambition to become a major player of the personalized and predictive medicine. We are a start-up benefiting from more than 30 years of research in the field of genomics. More specifically the company aims at bringing new solutions to practitioners involved in curing pathologies causing severe fibrosis evolving into cancers, myocardial infarction, skin scars, kidney failure.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ALLIGATOR BIOSCIENCE PRESENTS POSITIVE BIOMARKER DATA DEMONSTRATING PROOF OF MECHANISM IN MITAZALIMAB CLINICAL PHASE I STUDY

PR Newswir | September 04, 2020

news image

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today biomarker data from a recently performed clinical Phase I study of the drug candidate mitazalimab, its wholly owned CD40 antibody in development primarily for the treatment of pancreatic cancer. The data will be presented today at the scientific conference PEGS: The Essential Protein Engineering Summit being held virtually August 31- September 4, 2020."The presented biomarker data confirm the proof of mechanism and strengt...

Read More

CELL AND GENE THERAPY

EXACT SCIENCES ACQUIRES PREVENTIONGENETICS TO ACCELERATE AVAILABILITY OF HEREDITARY CANCER TESTING FOR MORE PATIENTS

Exact Sciences Corporation | January 10, 2022

news image

Exact Sciences Corp. announced it has acquired PreventionGenetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT). PreventionGenetics provides the clinical lab, expertise, and foundational technology necessary to accelerate the availability of HCT and help more patients know their germline risk of cancer and other diseases. "PreventionGenetics is a natura...

Read More

CELL AND GENE THERAPY

SARTORIUS STEDIM BIOTECH STRENGTHENS ITS PRODUCT PORTFOLIO FOR CELL AND GENE THERAPIES BY ACQUIRING A MAJORITY STAKE IN CELLGENIX

Sartorius | July 05, 2021

news image

Sartorius Stedim Biotech, a leading international biopharmaceutical partner, has acquired a majority stake in CellGenix GmbH, a reagent manufacturer. The company, headquartered in Freiburg, Germany, and with a sales subsidiary near the biotechnology center in Boston, Massachusetts, USA, manufactures and distributes cell culture components in GMP grade for the manufacture of cell and gene therapy products. Sartorius Stedim Biotech originally purchased 51% of this company, which was...

Read More

DOLCAS BIOTECH COMMITS TO ACCELERATING CLEAN-LABEL NUTRACEUTICALS FROM UPCYCLED RAW MATERIALS

PR Newswire | July 24, 2020

news image

DolCas Biotech, LLC, shares its zero-waste goal for the company's entire portfolio of potent branded nutraceutical ingredients. The company declared its commitment to accelerate a full-sustainability strategy centered on the upcycling of typically discarded — yet highly valuable — raw materials. DolCas will further ally this endeavor with its ongoing clean-label initiatives to maintain full transparency and traceability of its product line.According to Euromonitor Internati...

Read More
news image

ALLIGATOR BIOSCIENCE PRESENTS POSITIVE BIOMARKER DATA DEMONSTRATING PROOF OF MECHANISM IN MITAZALIMAB CLINICAL PHASE I STUDY

PR Newswir | September 04, 2020

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today biomarker data from a recently performed clinical Phase I study of the drug candidate mitazalimab, its wholly owned CD40 antibody in development primarily for the treatment of pancreatic cancer. The data will be presented today at the scientific conference PEGS: The Essential Protein Engineering Summit being held virtually August 31- September 4, 2020."The presented biomarker data confirm the proof of mechanism and strengt...

Read More
news image

CELL AND GENE THERAPY

EXACT SCIENCES ACQUIRES PREVENTIONGENETICS TO ACCELERATE AVAILABILITY OF HEREDITARY CANCER TESTING FOR MORE PATIENTS

Exact Sciences Corporation | January 10, 2022

Exact Sciences Corp. announced it has acquired PreventionGenetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT). PreventionGenetics provides the clinical lab, expertise, and foundational technology necessary to accelerate the availability of HCT and help more patients know their germline risk of cancer and other diseases. "PreventionGenetics is a natura...

Read More
news image

CELL AND GENE THERAPY

SARTORIUS STEDIM BIOTECH STRENGTHENS ITS PRODUCT PORTFOLIO FOR CELL AND GENE THERAPIES BY ACQUIRING A MAJORITY STAKE IN CELLGENIX

Sartorius | July 05, 2021

Sartorius Stedim Biotech, a leading international biopharmaceutical partner, has acquired a majority stake in CellGenix GmbH, a reagent manufacturer. The company, headquartered in Freiburg, Germany, and with a sales subsidiary near the biotechnology center in Boston, Massachusetts, USA, manufactures and distributes cell culture components in GMP grade for the manufacture of cell and gene therapy products. Sartorius Stedim Biotech originally purchased 51% of this company, which was...

Read More
news image

DOLCAS BIOTECH COMMITS TO ACCELERATING CLEAN-LABEL NUTRACEUTICALS FROM UPCYCLED RAW MATERIALS

PR Newswire | July 24, 2020

DolCas Biotech, LLC, shares its zero-waste goal for the company's entire portfolio of potent branded nutraceutical ingredients. The company declared its commitment to accelerate a full-sustainability strategy centered on the upcycling of typically discarded — yet highly valuable — raw materials. DolCas will further ally this endeavor with its ongoing clean-label initiatives to maintain full transparency and traceability of its product line.According to Euromonitor Internati...

Read More